{"schema_version":"secwatch.filing_event.v1","accession":"0001021771-24-000195","form_type":"8-K","ticker":"BRTX","cik":"0001505497","company_name":"BioRestorative Therapies, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.621775+00:00","generated_at":"2026-05-30T00:53:25.386419+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioRestorative Q3 operating loss narrows 26% YoY; BRTX-100 Phase 2 data shows improvement","bullets":["Q3 2024 operating loss $2.3M vs $3.1M YoY (26% improvement); net loss $1.1M ($0.13/sh).","Cash & equivalents $13.1M, no debt as of Sep 30, 2024.","$230,700 product revenue from Cartessa Aesthetics supply agreement in Q3.","Blinded Phase 2 data: 70% of 10 patients at 26 wks had >30% pain reduction, >30% function increase.","No SAEs or dose-limiting toxicity at 26–52 wks; provisional NYSDOH license for allogeneic processing."],"urls":{"canonical":"https://secwatch.observer/filing/0001021771-24-000195","json":"https://secwatch.observer/filing/0001021771-24-000195.json","markdown":"https://secwatch.observer/filing/0001021771-24-000195.md","text":"https://secwatch.observer/filing/0001021771-24-000195.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1505497/000102177124000195/0001021771-24-000195-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1505497/000102177124000195/brt8k111224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:53:25.386419+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}